BELLUS Health Inc. announced consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, the company reported revenues of CAD 0.599 million compared to CAD 0.568 million a year ago. Net loss attributable to owners of the company was CAD 0.537 million compared to CAD 3.193 million a year ago. Basic and diluted loss per share was CAD 0.01 compared to CAD 0.33 a year ago. The decrease is primarily due to a reduction in accretion expense and change in fair value of embedded derivative on convertible notes following the settlement of convertible securities, as part of the strategic partnership, financing and capital reorganization that took place in May 2012. Revenues mainly consist of revenue recognized for accounting purposes from the asset sale and license agreement as well as the service agreement entered into with Auven Therapeutics in 2010 for KIACTA(TM). Revenues also include revenue recognized for accounting purposes from the agreement with Asclepios Bioresearch (UK) Limited, as well as revenue from distribution agreements in relation to VIVIMIND(TM).

BELLUS Health Inc. (TSX:BLU) is seeking acquisitions. BELLUS Health said that the management is currently exploring opportunities in order to expand its pipeline, including through acquisitions and/or in-licensing.

BELLUS Health Inc. Presents at Bloom Burton & Co Healthcare Investor Conference, May-22-2013 04:00 PM. Venue: Toronto Board of Trade, 1 First Canadian Place, Toronto, ON M5X 1C1, Canada. Speakers: Roberto Bellini, Chief Executive Officer, President and Director.